George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlant Health Regulatory News (PHC)

Share Price Information for Plant Health (PHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.82
Bid: 3.70
Ask: 3.94
Change: 0.01 (0.26%)
Spread: 0.24 (6.486%)
Open: 3.81
High: 0.00
Low: 0.00
Prev. Close: 3.81
PHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

29 Jan 2016 07:00

RNS Number : 3769N
Plant Health Care PLC
29 January 2016
 

 

 

PLANT HEALTH CARE plc

 

("Plant Health Care" or the "Company")

 

 

Trading Update

 

Plant Health Care, a leading provider of novel patent-protected biological products to the global agriculture markets, issues the following post year-end trading update ahead of the announcement of the Company's audited full year financial results for the year ended 31st December 2015, which is expected no later than the first week of April. All results provided are preliminary and subject to completion of the 2015 audit.

 

The Company is pleased to report strong financial performance in FY2015 in line with expectations. Progress with our Plant Response Elicitor technology ("PREtec") platform has accelerated.

 

Financial and Commercial Highlights

- Revenue of approximately $7.5m; growth year over year at constant currency was 15%; 9% growth in US$, largely due to the weakness of the Mexican peso

- Sales of the core Harpin products increased by 22%, driven by strong sales in the United States and Europe; Harpin and Myconate® products represented 57% of sales in 2015 (2014: 53%)

- Gross Margin increased to 62% in 2015 from 51% in 2014

- Cash and cash equivalents at 31st December 2015 were $8.4m

- Revenue growth in Mexico of approximately 14% in local currency

- In conjunction with a significant increase in R&D investment to $5.7m in 2015, the overall operating result was a loss of approximately $7.3m in 2015 as compared to $6.1m in 2014

- A roughly two-fold increase in sales to Sym-Agro, a key partner in the Pacific North West

- Achieved the Company's first product registration in Brazil; now preparing for a launch in sugar cane

 

PREtec Highlights

- Signed four evaluation agreements with major players in the agriculture industry for our first family of PREtec peptides, Innatus 3G

- Completed third year of field trials in corn with Innatus 3G, including one peptide variant with three years of field trial data delivering an average yield increase of 9.6 bushels per acre when applied as a seed treatment compared with industry standard treatments alone, with a win rate of 79%, with data from 19 of 20 sites analyzed to date

- Very promising early results on additional peptide families beyond Innatus 3G

- Significantly strengthened the R&D team in Seattle and our licensing capability; moved into expanded laboratories in 3Q

 

Paul Schmidt, CEO, commented:

"2015 was a pivotal year for Plant Health Care. We made substantial progress in growing our commercial business and advancing our PREtec platform.

We are engaging actively with our evaluation partners for Innatus 3G, our first PREtec peptide family, and are encouraged by positive early results. Field and laboratory trials continue and are anticipated to further reinforce the initial promise of this family.

 

Our expanded research team in Seattle is making rapid strides, and we are very encouraged by the early results of studies on other peptide families beyond Innatus 3G. We intend to continue to evaluate and advance these additional peptide families and anticipate presenting at least one new family to potential partners during 2016.

On the commercial side, sales of Harpin αβ continued to grow; we have recorded 22% CAGR from 2012 to 2015, excluding license payments. This is despite strong headwinds in the agriculture industry due to low commodity prices. Increased demand for both Harpin αβ and Myconate in specialty crops has led to strong sales growth in our Mexico subsidiary as well as via Sym-Agro in the Pacific North West. In Brazil, our partner is conducting a further year of trials in sugar cane, prior to its anticipated launch of Harpin αβ.

 

This is an exciting time for Plant Health Care. We are advancing in line with our strategy and confident in our future direction."

 

 

For further information, please contact:

 

Plant Health Care plc

Paul Schmidt, Chief Executive Officer Tel: +1 919 926 1600

Jeffrey Hovey, Chief Financial Officer

 

Liberum Capital - Nomad and Broker

Clayton Bush / Chris Clarke Tel: +44 (0) 20 3100 2000

 

LHA

Ed McGregor / Jody Burfening Tel: +1 (212) 838 3777

 

Company website: www.planthealthcare.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTLFFVILSITFIR
Date   Source Headline
14th Nov 20187:00 amRNSPositive Developments with Harpin
8th Nov 20187:00 amRNSChange of Adviser
5th Nov 20187:00 amRNSHolding(s) in Company
18th Sep 20187:00 amRNSInterim Report ended 30 June 2018
12th Sep 20187:00 amRNSUS Announces Harpin aß Product Launch in Corn
20th Aug 20187:00 amRNSBlock listing Interim Review
30th Jul 20187:00 amRNSUpdate on sugarcane in Brazil
16th Jul 20187:00 amRNSTrading Statement
6th Jun 20182:39 pmRNSHolding(s) in Company
6th Jun 201811:14 amRNSResult of AGM
30th May 20187:00 amRNSGrant of Options
4th May 20185:59 pmRNSHolding(s) in Company
30th Apr 20183:11 pmRNSPublication of Annual Report and Notice of AGM
10th Apr 20187:00 amRNSResults for the year ended 31 December 2017
8th Mar 20187:00 amRNSBlock listing Interim Review
7th Mar 20183:07 pmRNSHolding(s) in Company
7th Mar 20183:06 pmRNSHolding(s) in Company
7th Mar 20183:02 pmRNSHolding(s) in Company
2nd Mar 20185:48 pmRNSHolding(s) in Company
27th Feb 20184:12 pmRNSResult of Placing and Subscription
27th Feb 20187:00 amRNSProposed Placing and Subscription
24th Jan 20187:00 amRNSTrading Statement
12th Dec 20177:00 amRNSNew Technology Update
8th Dec 20174:35 pmRNSPrice Monitoring Extension
6th Dec 20174:40 pmRNSSecond Price Monitoring Extn
6th Dec 20174:35 pmRNSPrice Monitoring Extension
18th Sep 20177:00 amRNSHalf-year Report
21st Aug 20177:00 amRNSBlock listing Interim Review
3rd Aug 20177:00 amRNSHolding(s) in Company
12th Jul 20174:09 pmRNSGrant of options
30th Jun 20173:30 pmRNSHolding(s) in Company
15th Jun 20177:00 amRNSDirector/PDMR Shareholding
8th Jun 20174:35 pmRNSPrice Monitoring Extension
6th Jun 20177:00 amRNSNew Technology Update
31st May 20177:00 amRNSDirector/PDMR Shareholding
26th May 20177:00 amRNSDirector/PDMR Shareholding
22nd May 20177:00 amRNSGrant of options
11th May 201712:50 pmRNSResult of AGM
27th Apr 20177:00 amRNSPublication of Annual Report and Notice of AGM
10th Apr 20177:00 amRNSResults for the Year Ended 31 December 2016
5th Apr 20174:49 pmRNSChange of Registered Office
5th Apr 20177:00 amRNSHolding(s) in Company
5th Apr 20177:00 amRNSHolding(s) in Company
20th Feb 20177:01 amRNSDirector/PDMR Shareholding
20th Feb 20177:00 amRNSBlock listing Interim Review
8th Feb 20177:00 amRNSHolding(s) in Company
18th Jan 20177:02 amRNSResearch Update
18th Jan 20177:00 amRNSTrading Statement
19th Dec 20164:40 pmRNSSecond Price Monitoring Extn
19th Dec 20164:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.